HC Wainwright Estimates OTCMKTS:BSEM Q1 Earnings

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of BioStem Technologies in a research note issued to investors on Wednesday, May 6th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.28) for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for BioStem Technologies’ current full-year earnings is $0.29 per share. HC Wainwright also issued estimates for BioStem Technologies’ Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.05 EPS, FY2026 earnings at ($0.26) EPS, Q1 2027 earnings at $0.05 EPS, Q2 2027 earnings at $0.10 EPS, Q3 2027 earnings at $0.23 EPS, Q4 2027 earnings at $0.21 EPS, FY2027 earnings at $0.59 EPS, FY2028 earnings at $0.79 EPS, FY2029 earnings at $1.10 EPS and FY2030 earnings at $1.40 EPS.

Separately, Zacks Research raised shares of BioStem Technologies to a “hold” rating in a report on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, BioStem Technologies presently has an average rating of “Buy” and a consensus price target of $9.00.

BioStem Technologies Stock Up 1.1%

Shares of BSEM stock opened at $4.55 on Tuesday. The company has a 50 day moving average of $4.88 and a 200-day moving average of $4.84. BioStem Technologies has a 12-month low of $3.09 and a 12-month high of $15.45. The firm has a market cap of $77.26 million, a P/E ratio of -10.73 and a beta of 0.09.

Key Headlines Impacting BioStem Technologies

Here are the key news stories impacting BioStem Technologies this week:

• Positive Sentiment: HC Wainwright maintained a Strong-Buy rating on BioStem Technologies and projected earnings to turn from a loss in FY2026 to positive earnings growth in FY2027 and beyond, with FY2027 EPS estimated at $0.59 and FY2030 at $1.40. BioStem Technologies stock page
• Neutral Sentiment: The firm’s quarterly estimates suggest a gradual earnings recovery through 2026 and 2027, including a loss in Q1 2026, smaller losses in Q2 2026, and positive EPS by later quarters, which may reinforce a longer-term turnaround narrative. BioStem Technologies stock page

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.